Document Type: Original Article

Authors

1 Department of Emergency Medicine, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Research Centre for Patient Safety, Mashhad University of Medical Sciences, Mashhad, Iran

3 Taleghani Hospital, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

Objective: Septic shock is a response to infection and tissue hypoperfusion which does not respond to fluid therapy and eventually leads to organ dysfunction. Aggressive treatment of a broad-spectrum antimicrobial and supportive measures are the cornerstones of successful treatment. In addition to the main treatment, there are adjunctive therapies. Steroids are one of the treatments which have been studied in the management of refractory septic shock. Despite numerous studies on the role of steroids in the mortality of severe sepsis and septic shock, still lots of controversies exist. These conflicts are often about the steroid dose and duration of administration.
Methods: This was a prospective, randomized-controlled, two-group assignment study. Patients referred to Imam Reza (AS) hospital in Mashhad who had refractory septic shock criteria were randomly divided into two groups: 80 patients were included in each group. After obtaining the baseline cortisol level and cosyntropin test, one group was treated with intravenous hydrocortisone, and the other group was treated with placebo. The response to hydrocortisone, the return of shock duration, and mortality at 28 days were investigated. The data were analyzed using SPSS version 16. For the normally distributed variables, a t test was used for comparisons. Concerning qualitative variables, the chi-square test or Fisher exact test were applied accordingly.
Results: The return of shock duration and mortality in intervention group patients was more than control group, but it was not statistically significant.
Conclusion: Despite numerous studies in this field, there are various outcomes (mortality rate, rate of return of shock, time of return of shock). These differences can be attributed to high degree of heterogeneity. Perhaps considering the underlying disease and more differentiation could change the return of shock and mortality rate.

Keywords

Main Subjects

1. Munford RS, Suffredini AF. Sepsis, severe sepsis, and septic shock. In: Mandell GL, Bennett JE, Dolin R, eds. Principles
and Practice of Infectious Diseases. London: Elsevier/Churchill-Livingstone; 2005. p. 906-26.

2. Shapiro NI, Zimmer GD, Barkin AZ. Sepsis syndromes. In: Marx, JA, Hockberger RS, Walls RM, eds. Rosen’s Emergency Medicine: Concepts and Clinical Practice. 8th ed. Philadelphia, PA: Elsevier Saunders; 2014.

3. Tunctan B, Korkmaz B, Sari AN, Kacan M, Unsal D, Serin MS, et al. A novel treatment strategy for sepsis and septic
shock based on the interactions between prostanoids, nitric oxide, and 20-hydroxyeicosatetraenoic acid. Antiinflamm
Antiallergy Agents Med Chem 2012; 11(2): 121-50.

4. Patel GP, Balk RA. Systemic steroids in severe sepsis and septic shock. Am J Respir Crit Care Med 2012; 185(2): 133-9. doi: 10.1164/rccm.201011-1897CI.

5. Annane D. Corticosteroids for severe sepsis: an evidencebased guide for physicians. Ann Intensive Care 2011; 1(1):
7. doi: 10.1186/2110-5820-1-7.

6. Dellinger RP, Levy MM, Carlet JM, Bion J, Parker MM, Jaeschke R, et al. Surviving sepsis campaign: international
guidelines for management of severe sepsis and septic shock: 2008. Crit Care Med 2008; 36(1): 296-327.

7. Arafah BM. Hypothalamic pituitary adrenal function during critical illness: limitations of current assessment methods. J Clin Endocrinol Metab 2006; 91(10): 3725-45.

8. Marik PE, Pastores SM, Annane D, Meduri GU, Sprung CL, Arlt W, et al. Recommendations for the diagnosis and management of corticosteroid insufficiency in critically ill adult patients: consensus statements from an international task force by the American College of Critical Care Medicine. Crit Care Med 2008; 36(6): 1937-49. doi:10.1097/CCM.0b013e31817603ba.

9. Annane D, Sébille V, Troché G, Raphaël JC, Gajdos P, Bellissant E. A 3-level prognostic classification in septic shock based on cortisol levels and cortisol response to corticotropin. JAMA 2000; 283(8): 1038-45.

10. Bollaert PE, Charpentier C, Levy B, Debouverie M, Audibert G, Larcan A. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26(4): 645-50.

11. Yildiz O, Doğanay M, Aygen B, Güven M, Keleştimur F, Tutuş A. Physiological-dose steroid therapy in sepsis [ISRCTN36253388]. Crit Care 2002; 6(3): 251-9. doi:10.1186/cc1498.

12. Oppert M, Schindler R, Husung C, Offermann K, Gräf K-J, Boenisch O, et al. Low-dose hydrocortisone improves shock
reversal and reduces cytokine levels in early hyperdynamic septic shock. Crit Care Med 2005; 33(11): 2457-64.

13. Sprung CL, Annane D, Keh D, Moreno R, Singer M, Freivogel K, et al. Hydrocortisone therapy for patients with septic shock. N Engl J Med 2008; 358(2): 111-24. doi:10.1056/NEJMoa071366.

14. Annane D, Bellissant E, Bollaert PE, Briegel J, Confalonieri M, De Gaudio R, et al. Corticosteroids in the treatment of
severe sepsis and septic shock in adults: a systematic review. JAMA 2009; 301(22): 2362-75. doi:10.1001/jama.2009.815.

15. Wang C, Sun J, Zheng J, Guo L, Ma H, Zhang Y, et al. Lowdose hydrocortisone therapy attenuates septic shock in
adult patients but does not reduce 28-day mortality: a metaanalysis of randomized controlled trials. Anesth Analg 2014;
118(2): 346-57. doi: 10.1213/ANE.0000000000000050.

16. Sherwin RL, Garcia AJ, Bilkovski R. Do low-dose corticosteroids improve mortality or shock reversal in patients with septic shock? A systematic review andposition statement prepared for the American Academy of Emergency Medicine. J Emerg Med 2012; 43(1): 7-12. doi:10.1016/j.jemermed.2011.08.015.

17. Casserly B, Gerlach H, Phillips GS, Lemeshow S, Marshall JC, Osborn TM, et al. Low-dose steroids in adult septic
shock: results of the Surviving Sepsis Campaign. Intensive Care Med 2012; 38(12): 1946-54. doi: 10.1007/s00134-012-
2720-z.

18. Dalegrave D, Silva RL, Becker M, Gehrke LV, Friedman G. Relative adrenal insufficiency as a predictor of disease
severity and mortality in severe septic shock. Rev Bras Ter Intensiva 2012; 24(4): 362-8. doi: 10.1590/S0103-
507X2012000400012.

19. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving Sepsis Campaign Guidelines
Committee including the Pediatric Subgroup Surviving sepsis campaign: international guidelines for management
of severe sepsis and septic shock: 2012. Intensive Care Med 2013; 39(2): 165-228. doi: 10.1007/s00134-012-2769-8.

20. Chen Z, Yang C, He H, He Z. The impacts of low-dose corticosteroids infusion given in different manners on
refractory septic shock patients. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue 2015; 27(6): 443-7. doi: 10.3760/cma.j.is
sn.2095-4352.2015.06.006. [In Chinese].

21. Briegel J, Bein T, Möhnle P. Update on low-dose corticosteroids. Curr Opin Anaesthesiol 2017; 30(2): 186-191.doi: 10.1097/ACO.0000000000000442.

22. Tagami T, Matsui H, Fushimi K, Yasunaga H. Low-dose corticosteroid treatment and mortality in refractory abdominal septic shock after emergency laparotomy. Ann Intensive Care 2015; 5(1): 32. doi: 10.1186/s13613-015-0074-8.

23. Torres A, Sibila O, Ferrer M, Polverino E, Menendez R, Mensa J, et al. Effect of corticosteroids on treatment failure
among hospitalized patients with severe communityacquired pneumonia and high inflammatory response: a
randomized clinical trial. JAMA 2015; 313(7): 677-86. doi:10.1001/jama.2015.88.

24. Volbeda M, Wetterslev J, Gluud C, Zijlstra J, van der Horst I, Keus F. Glucocorticosteroids for sepsis: systematic review
with meta-analysis and trial sequential analysis. Intensive Care Med 2015; 41(7): 1220-34. doi: 10.1007/s00134-015-
3899-6.